Sarcomeric hypertrophic cardiomyopathy (HCM) is a prevalent genetic disorder
characterised by left ventricular hypertrophy, myocardial disarray, and an increased risk of …

Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower
left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients …

Cardiomyopathy, a heterogeneous pathological condition characterized by changes in
cardiac structure or function, represents a significant risk factor for the prevalence and …

Cuproptosis is a recently reported new mode of programmed cell death which might be a
potential co-pathogenesis of three kinds of primary cardiomyopathy. However, no …

Background There is limited data examining potential sex-based disparities in the utilization
and complications of septal reduction therapy (SRT) in patients with obstructive hypertrophic …

Background Familial hypertrophic cardiomyopathy (HCM) is the most common genetic
cardiovascular disease. Related mutations contributing to hypercontractility and poor …

肥厚型梗阻性心肌病(hypertrophic obstructive cardiomyopathy， HOCM)
是一种以心室间隔肥厚和左心室流出道梗阻为主要特征的遗传性心脏疾病 …

Aim The impact of hypertension (HT) on phenotypic expression in individuals with
hypertrophic cardiomyopathy (HCM) is unclear. Materials and methods Thirty-six HCM …

Background: Right ventricular involvement in hypertrophic cardiomyopathy is uncommon.
This study aimed to evaluate clinical outcomes of the modified septal myectomy in patients …

肥厚型梗阻性心肌病 (hypertrophic obstructive cardiomyopathy, HOCM)
是一种以心室间隔肥厚和左心室流出道梗阻为主要特征的遗传性心脏疾病. 传统的治疗方法 …